Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence

Trial Profile

Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence

Phase of Trial: Phase II/III

Latest Information Update: 10 Feb 2018

At a glance

  • Drugs Gallium 68 PSMA (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Diagnostic use
  • Most Recent Events

    • 10 Feb 2018 Results of a pooled analysis of NCT02918357 & NCT02611882 (n=158) in detection of prostate cancer lesions using Gallium-68 PSMA-11 PET in men with biochemical recurrence following radical prostatectomy, presented at the 2018 Genitourinary Cancers Symposium
    • 16 Nov 2017 Status changed from active, no longer recruiting to completed.
    • 21 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top